Clinical evaluation of a functional prothrombin time-based assay for identification of factor V Leiden carriers in a group of Italian patients with venous thrombosis

Blood Coagulation and Fibrinolysis

Volumn 18, Issue 7, 2007, Pages 603-610

  Gessoni, Gianluca ^a   Valverde, Sara ^a  

^a Ospedale Civile Dolo   (Italy)

Author keywords

Activated protein C resistance; Factor V Leiden; Functional assay; Interference; Prothrombin time; Thrombophilia

Indexed keywords

ACTIVATED PROTEIN C; BLOOD CLOTTING FACTOR 5; BLOOD CLOTTING FACTOR 5 LEIDEN; PROTHROMBIN; REAGENT;

ADULT; AGED; ARTICLE; AUTHOR; BLOOD CLOTTING FACTOR 5 DEFICIENCY; CLINICAL EVALUATION; COMPARATIVE STUDY; DEEP VEIN THROMBOSIS; DILUTION; DRUG IDENTIFICATION; EXPERIENCE; FEMALE; HETEROZYGOTE; HOMOZYGOTE; HUMAN; ITALY; MAJOR CLINICAL STUDY; MALE; MUTATION; PRIORITY JOURNAL; PROTHROMBIN TIME; SAMPLE; SENSITIVITY AND SPECIFICITY;

ACTIVATED PROTEIN C RESISTANCE; ADULT; AGED; CASE-CONTROL STUDIES; FACTOR V; FEASIBILITY STUDIES; FEMALE; HETEROZYGOTE; HOMOZYGOTE; HUMANS; ITALY; MALE; MIDDLE AGED; POLYMERASE CHAIN REACTION; PROTEIN C; PROTHROMBIN; PROTHROMBIN TIME; RISK FACTORS; SENSITIVITY AND SPECIFICITY; THROMBOPHILIA; VENOUS THROMBOSIS;

EID: 34748922294     PISSN: 09575235     EISSN: None     Source Type: Journal    
DOI: 10.1097/MBC.0b013e3282891e2f     Document Type: Article

References (21)

1. Tripodi A, Mannucci P. Laboratory investigation of thrombophilia. Clin Chem 2001; 47:1597-1606.
2. Somma J, Sussman I, Rand J. An evaluation of thrombophilia screening in an urban tertiary care medical center: a 'real world' experience. Am J Clin Pathol 2006; 126:1-8.
3. League S, Hooper W. Molecular diagnosis of inherited thrombosis. Clin Lab Sci 2005; 18:271-279.
4. Saynalp N, Haznedaroglu I, Aksu S, Buyukasik Y, Goker H, Parlak H, et al. The predictability of factor V Leiden (FV:Q506) gene mutation via clotting based diagnosis of activated protein C resistance. Clin Appl Thromb Hemost 2004; 10:265-270.
5. Wilmer M, Stocker C, Buhler B, Conell B, Calatzis A. Improved distinction of factor V wild-type and factor V Leiden using a novel prothrombin based activated protein C resistance assay. Am J Clin Pathol 2004; 122:836-842.
6. Moll S. Thrombophilias - practical implications and testing caveat. J Thromb Thrombolysis 2006; 21:7-15.
7. De Stefano V, Rossi E, Paciaroni K, Leone G. Screening for inherited thrombophilia: indications and therapeutic implications. Haematologica 2002; 87:1095-1108.
8. Paschoa A, Guillaumon A. Impact of screening on thrombophilia for patients with venous thrombosis. Int Angiol 2006; 25:52-59.
9. Franchini M, Veneri D, Salvagno G, Manzato F, Lippi G. Inherited thrombophilia. Crit Rev Clin Lab Sci 2006; 43:249-250.
10. Castoldi E, Kalafatis M, Lunghi B, Simioni P, Ioannou P, et al. Molecular bases of pseudo homozygous APC resistance: the compound heterozygosity for FV R506Q and FV null mutation results in the exclusive presence of FV Leiden molecules in plasma. Thromb Haemost 1998; 9:403-406.
11. Guerrero F, Arnaud C, Nguyen F, Boneu B, Sie P. Comparison of three activated protein C test in the risk assessment of venous thrombosis in non carriers of the factor V Leiden mutation. Thromb Haemost 2006; 4:728-734.
12. Brugge J, Simioni P, Bernardi F, Tormene D, Lunghi B, Tans G, et al. Expression of the normal factor V allele modulates the APC resistance phenotype in heterozygous carriers of the factor V Leiden mutation. J Thromb Haemost 2005; 3:2695-2702.
13. Delahousse B, Iochmann S, Pouplard C, Fimbel B, Charbonnier B, Gruel Y. Psuedo homozygous activated proteinC resistance due to coinheritance of heterozygous factor V Leiden mutation and tyoe I factor V deficiency. Variable expression when analyzed by different activated proteinCresistance functional assays. Blood Coagul Fibrinolysis 1997; 8:503-509.
14. Lunghi B, Scanavini D, Castoldi E, Gemmati D, Tognazzo S, Redaelli R, et al. The factor V Glu1608Lys mutation is recurrent in familial thrombophilia. J Thromb Haemost 2005; 3:2032-2038.
15. Nojima J, Kuratsume H, Suehisa E, Iwatani Y, Kanakura Y. Acquired activated protein C resistance associated with IgG antibodies against beta2 glycoprotein I and prothrombin as a strong risk factor for venous thromboembolism. Clin Chem 2005; 51:545-552.
16. Bokarewa M, Blombak M. Combination of activated protein C resistance and antibodies to phospholipids in the development of thrombosis. Semin Hematol 1997; 34:235-243.
17. Ragland B, Reed C, Eiland B, Tichenor P, Hudson C, Fritsma GA, et al. The effect of lupus anticoagulant in the second generation assay for activated protein C resistance. Am J Clin Pathol 2003; 119:66-71.
18. Schoni R, Quehenberger P, Wu J, Wilmer M. Clinical evaluation of a new functional test for detection of activated protein C resistance Pefakit APCR Factor V Leiden at two centers in Europe and the USA. Thromb Res 2007; 119:17-26.
19. De Visser M, van Hylckama V, Tans G, Rosing J, Dahm A, Sandset PM, et al. Determinants of APTT and ETP based APC sensitivity tests. J Thromb Haemost 2005; 3:1488-1494.
20. Zarychanski R, Houston D. Plasma homocysteine concentration is not assocaited with activated protein C resistance in patients investigated for hypercoagulability. Thromb Haemost 2004; 91:1115-1122.
21. Bauduer F, Lacombe D. Factor V Leiden, prothrombin 20210A, methlylene tetra hydrofolate reductase 677T and population genetics. Mol Genet Metab 2005; 86:91-99.